Biogen Idec edges out Street

Biogen Idec Inc. (NASDAQ:BIIB) reported 4Q11 non-GAAP diluted EPS of $1.51, beating by $0.02 the Street's estimate of $1.49 and up 6% from $1.42 in 4Q10. Fourth quarter revenues were $1.33 billion, slightly above the Street's $1.29 billion estimate and up 9% from $1.22 billion in 4Q10. Global sales of autoimmune drug Tysabri natalizumab were $380 million, up 14% from 4Q10. Biogen Idec recognized $269 million in Tysabri revenue, up 11% from $241.6 million in 4Q10. The autoimmune drug is partnered with Elan Corp. plc (NYSE:ELN). Fourth quarter revenues for Avonex interferon beta-1a for multiple sclerosis (MS) rose 8% to $703 million. ...